Significant Ownership of New Enterprise Associates 17, L.P.

Signature - Title
/s/ Zachary Bambach - Zachary Bambach as attorney-in-fact for Anthony A. Florence, Jr., Managing Partner and Co-Chief Executive Officer
Location
Timonium, MD
Summary
This page shows a list of all the recent SCHEDULE 13D/G filings made by New Enterprise Associates 17, L.P..

Follow Filing Activity

Follow New Enterprise Associates 17, L.P. and return when a new Schedule 13D/G filing appears.

This tracks SEC filing changes for this page using existing product update flows.

Sponsored

Significant Ownership of New Enterprise Associates 17, L.P.

Sym Company Class Ownership Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
SpyGlass Pharma, Inc. Common Stock, $0.00001 par value per share 22% 7,393,823 Ali Behbahani 09 Feb 2026
KRRO Korro Bio, Inc. Common Stock, par value $0.001 per share 9.9% $17,130,522 1,456,677 Ali Behbahani 10 Mar 2026
GLUE Monte Rosa Therapeutics, Inc. Common Stock, par value $0.0001 per share 9.7% $143,153,471 7,797,030 Ali Behbahani 17 Mar 2026
MBX MBX Biosciences, Inc. Common Stock, par value $0.0001 per share 8.1% $63,340,795 3,619,474 Edward T. Mathers 06 Nov 2025
IVA Inventiva S.A. Ordinary Shares, (euro)0.01 par value per share 4.9% $57,827,646 +$6,303,642 9,372,390 +12% New Enterprise Associates 17, L.P. 30 Mar 2026
NEUE NeueHealth, Inc. Common Stock, $0.0001 par value 0% $0 -$50,344,650 0 -100% New Enterprise Associates 15, L.P. 02 Oct 2025

Schedules 13D/G Reported by New Enterprise Associates 17, L.P.:

Sym Target Class Ownership Change Current Shares Change Value Reporting name Form Report Period Filing Date
* An asterisk sign (*) next to the price indicates that the price is likely invalid.